原发性中枢神经系统淋巴瘤的治疗

摘要/Abstract

摘要：原发性中枢神经系统淋巴瘤（PCNSL）是一种较少见的中枢神经系统恶性肿瘤，总体预后欠佳，主要治疗方法包括手术、放疗和化疗。立体定向活检术以其微创、便捷的优点，已经成为确诊PCNSL的常规方法。全脑放疗是多病灶性PCNSL的标准化治疗方法，可短期内延缓肿瘤进展。以大剂量甲氨蝶呤为基础的治疗方案大大改善了PCNSL的治疗效果，成为PCNSL的有效治疗措施。有效的综合治疗是延长PCNSL患者生存期和改善生命质量的关键。

关键词:淋巴瘤,中枢神经系统肿瘤,放射疗法,药物疗法,甲氨蝶呤

Abstract:As a kind of rare central nervous system malignant tumor, primary central nervous system lymphoma (PCNSL) has poor prognosis, and the main treatment include surgery, radiotherapy and chemotherapy. Stereotactic biopsy has become a routine diagnostic method of PCNSL, because of which has the advantage of minimally invasive and convenient. Whole brain radiotherapy is a standardized treatment method for the multifocal PCNSL, which can delay the progress of tumor in a short term. The therapeutic regimen based on high dose methotrexate leads to significant changes in the PCNSL treatment and it has become an effective treatment measure. Effective comprehensive treatment is the key to extending survival time and improving the quality of life for the patients with PCNSL.

Key words:Lymphoma,Central nervous system neoplasms,Radiotherapy,Drug therapy,Methotrexate

李小优,冯继锋. 原发性中枢神经系统淋巴瘤的治疗[J]. 国际肿瘤学杂志, 2016, 43(1): 71-74.

Li Xiaoyou, Feng Jifeng. Treatment of primary central nervous system lymphoma[J]. Journal of International Oncology, 2016, 43(1): 71-74.

参考文献

［1］ Nayak L, Batchelor TT. Recent advances in treatment of primary central nervous system lymphoma［J］. Curr Treat Options Oncol, 2013, 14(4): 539-552. DOI:10.1007/s11864-013-0252-6. ［2］ Korfel A, Schlegel U. Primary CNS lymphoma. Progress in the diagnostics and therapy［J］. Nervenarzt, 2015, 86(6): 710715. DOI:10.1007/s00115-014-4227-z. ［3］朴颖哲, 李鹏, 刘群, 等. 原发性中枢神经系统淋巴瘤23例临床分析［J］. 中华内科杂志, 2011, 50(11): 954-957. DOI:10.3760/cma.j.issn.0578-1426.2011.11.013. ［4］ Joerger M, Huitema AD, Krhenbühl S, et al. Methotrexate area under the curve with is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokineticpharmacodynamic analysis from the IELSG no.20 trial［J］. Br J Cancer, 2010, 102(4): 673-677. DOI:10.1038/sj.bjc.6605559. ［5］ Thiel E, Korfel A, Martus P, et al. Highdose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (GPCNSLSG1): a phase 3, randomised, noninferiority trial［J］. Lancet Oncol, 2010, 11(11): 1036-1047. DOI:10.1016/S1470-2045(10)70229-1. ［6］ Kadoch C, Li J, Wong VS, et al. Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma［J］. Clin Cancer Res, 2014, 20(4): 10291041. DOI:10.1158/1078-0432.CCR-13-0474. ［7］ Xu G, Yang M, Tong H, et al. Highdose methotrexate plus temozolomide as a salvage treatment in metastatic central nervous system lymphoma: two cases report and review of literature［J］. Int J Clin Exp Med, 2015, 8(5): 8222-8225. ［8］ Reni M, Zaja F, Mason W, et al. Temozolomide as salvage treatment in primary brian lymphomas［J］. Br J Cancer, 2007, 96(6): 864-867. DOI:10.1038/sj.bjc.6603660. ［9］ Kurzwelly D, Glas M, Roth P, et al. Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status［J］. J Neurooncol, 2010, 97(3): 389-392. DOI:10.1007/s11060-009-0032-0. ［10］ Wong ET, Tishler R, Barron L, et al. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas［J］. Cancer, 2004, 101(1): 139-145. DOI:10.1002/cncr.20339. ［11］ Ishiura Y, Shiba Y, Ikeda H, et al. Analysis of factors associated with the quality of life in patients with nonsmall cell lung cancer who received outpatient pemetrexed maintenance therapy［J］. Gan To Kagaku Ryoho, 2014, 41(6): 761-764. ［12］ Wang Y, Wang X, Zhao Y, et al. Curative effect of pemetrexed on the treatment of relapsed primary central nervous system lymphoma［J］. Zhonghua Xue Ye Xue Za Zhi, 2014, 35(1): 46-49. DOI:10.3760/cma.j.issn.0253-2727.2014.01.012. ［13］ Raizer JJ, Rademaker A, Evens AM, et al. Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma［J］. Cancer, 2012, 118(15): 3743-3748. DOI:10.1002/cncr.26709. ［14］王勇, 刘保岩, 许德志, 等. 17例复发性原发中枢神经系统淋巴瘤的临床观察［J］. 临床肿瘤学杂志, 2013, 18(4): 364-367. ［15］ Illerhaus G, Müller F, Feuerhake F, et al. Highdose chemotherapy and autologous stemcell transplantation without consolidating radiotherapy as firstline treatment for primary lymphoma of the central nervous system［J］. Haematologica, 2008, 93(1): 147-148. DOI:10.3324/haematol.11771. ［16］ Colombat P, Lemevel A, Bertrand P, et al. Highdose chemotherapy with autologous stem cell transplantation as firstline therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group［J］. Bone Marrow Transplant, 2006, 38(6): 417-420. DOI:10.1038/sj.bmt.1705452. ［17］陆晓林, 朱海燕, 靖彧, 等. 自体造血干细胞移植治疗原发中枢神经系统淋巴瘤2例并文献复习［J］. 临床荟萃, 2014, 29(6): 640-643. DOI:10.3769/j.issn.1004583X.2014.06.013. ［18］ Riganti C, Salaroglio IC, PinzònDaza ML, et al. Temozolomide downregulates Pglycoprotein in human bloodbrain barrier cells by disrupting Wnt3 signaling［J］. Cell Mol Life Sci, 2014, 71(3): 499-516. DOI:10.1007/s00018-013-1397-y. ［19］ Attia SM. Molecular cytogenetic evaluation of the aneugenic effects of teniposide in somatic and germinal cells of male mice［J］. Mutagenesis, 2012, 27(1): 31-39. DOI:10.1093/mutage/ger051. ［20］ Wu JJ, Wang XH, Li L, et al. Fotemustine, teniposide and dexamethasone in treating patients with CNS lymphoma［J］. Asian Pac J Cancer Prev, 2014, 15(11): 4733-4738. ［21］ Bernard S, Goldwirt L, Amorim S, et al. Activity with ibrutinib in mantle cell lymphoma patients with central nervous system relapse［J］. Blood, 2015, 126（14）： 1695-1698. DOI:10.1182/blood-2015-05-647834. ［22］ Houillier C, Choquet S, Touitou V, et al. Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma［J］. Neurology, 2015, 84(3): 325-326. DOI:10.1212/WNL.0000000000001158.

[1]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[2]	张洁, 范玲, 李杰, 温华, 苏媛媛, 路宁, 张明鑫.原发性胰腺淋巴瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 316-320.
[3]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵.寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[4]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安.新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[5]	金旭东, 陈忠坚, 毛伟敏.MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.
[6]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会.中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[7]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟.基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[8]	崔腾璐, 吕璐, 孙鹏飞.放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用[J]. 国际肿瘤学杂志, 2023, 50(9): 548-552.
[9]	李晨曦, 赵宏伟.二次肿瘤细胞减灭术治疗初始减瘤手术不满意铂敏感复发性卵巢癌的预后及影响因素分析[J]. 国际肿瘤学杂志, 2023, 50(6): 342-347.
[10]	李青珊, 谢鑫, 张楠, 刘帅.放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[11]	许萌, 姜伟, 朱海涛, 曹雄锋.癌相关成纤维细胞在肿瘤放疗抵抗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 227-230.
[12]	石小琪, 汪红艳.肠道菌群与放射性肠炎的相互作用及研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 244-247.
[13]	李进芝, 赵彪, 文晓博, 张明, 袁美芳, 孙梦真, 蒲琴, 杨毅.Monaco系统计算网格尺寸对T₄期鼻咽癌的剂量学影响[J]. 国际肿瘤学杂志, 2023, 50(11): 641-649.
[14]	耿睿, 马俊强, 郭强, 牛钊峰.老年乳腺癌患者的综合治疗方式选择倾向及其影响因素[J]. 国际肿瘤学杂志, 2023, 50(11): 650-654.
[15]	王冰, 王爱馥, 刘雯舒, 范娇娇, 田伟成, 王玮莉, 刘博宇.重组人血小板生成素治疗肿瘤放疗所致血小板减少症的疗效及安全性[J]. 国际肿瘤学杂志, 2023, 50(11): 661-667.